BofA lowered the firm’s price target on Carlyle to $30 from $31 and keeps an Underperform rating on the shares. In its earnings preview for the alternative asset managers, the firm notes that Q3 financial results were impacted by several headwinds that include negative markets, rising defaults and restructurings, higher interest rates, offset by positives that include realizations, investing, retail flows and improving trends. Ahead of Q3 reports, the firm adjusts its estimates and reduced its price targets for “most Alts” it covers.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CG:
- Wolfe Research initiates the Alternative Asset Managers at Market Overweight
- Carlyle initiated with a Peer Perform at Wolfe Research
- Acentra Health awarded $52.3M contract from U.S. VA
- Carlyle in talks to acquire two Medtronic units for over $7B, Reuters says
- The SEC’s Crackdown on Wall Street’s Use of WhatsApp Continues